Fluorescein
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fluorescein: From Diagnostic Ophthalmic Dye to Prinzmetal Angina
One-Sentence Summary
Fluorescein is a fluorescent diagnostic dye used in ophthalmology, for retinal angiography and for staining the ocular surface. The TxGNN model predicts it may be relevant to Prinzmetal angina, but no clinical trials and no supporting publications back this prediction. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the registration data compiled for this report (products are an injection for retinal angiography and ophthalmic staining strips) |
| Predicted New Indication | Prinzmetal angina |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Fluorescein is a diagnostic fluorescent dye. It is given by injection for retinal angiography and applied topically to stain the ocular surface. It is not known to have therapeutic pharmacological activity.
The review of the prediction found no plausible mechanistic link between fluorescein and Prinzmetal angina. The condition is driven by coronary vasospasm, and fluorescein has no known vasodilatory or anti-vasospastic action. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should be read as a hypothesis-generating signal, not as evidence of benefit.
Other predictions were also reviewed:
- Rheumatoid arthritis, hemoglobinopathy, thrombophilia and hyperthyroidism: The retrieved literature mostly describes eye findings in these diseases, where fluorescein is used as a diagnostic tool. This reflects diagnostic co-occurrence, not treatment evidence.
- Antithrombin deficiency type 2, factor 5 excess, heparin cofactor 2 deficiency, partial deletion of the short arm of chromosome 16, and beta-thalassemia with other manifestations: These have no trials, no literature and no mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No publications directly support fluorescein as a treatment for Prinzmetal angina. Currently no related literature available for this indication.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 187812 | Retigraph 20% Injection | Vial of 3 ml injection | Not specified |
| 89133 | Fluore Stain 0.45mg Strip | Packet of 100 ophthalmic solution | Not specified |
| 88377 | Floure Stain Strip | Packet of 100 ophthalmic solution | Not specified |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications, and no plausible mechanism links this diagnostic dye to coronary vasospasm. The other nine predicted indications are also at L4–L5, and the literature for them reflects diagnostic use of fluorescein rather than therapy.
To proceed, the following is needed:
- Mechanism of action data and a testable pharmacological hypothesis for Prinzmetal angina
- Package insert warnings and contraindications for the marketed products
- Approved indication text for the three registrations
- Any preclinical or clinical evidence of vasoactive or therapeutic effect, which does not currently exist in the data compiled for this report
- Route compatibility assessment, since the marketed forms are an injection and an ophthalmic strip
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.